WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581189

CAS#: 43021-45-0

Description: Dacuronium is a new steroidal drug of the neuromuscular blocking properties.Dacuronium produced a competitive type of neuromuscular block with a potency of approximately one-tenth that of tubocurarine and one-fiftieth that of pancuronium. Dacuronium, on the other hand, would appear to have marked chronotropic effects at dose levels needed for adequate neuromuscular blockade.

Chemical Structure

CAS# 43021-45-0

Theoretical Analysis

MedKoo Cat#: 581189
Name: Dacuronium
CAS#: 43021-45-0
Chemical Formula: C33H58N2O32+
Exact Mass: 530.4436
Molecular Weight: 530.84
Elemental Analysis: Chemical Formula: C33H58N2O32+ Exact Mass: 530.4436 Molecular Weight: 530.8369 Elemental Analysis: C, 74.67; H, 11.01; N, 5.28; O, 9.04

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Dacuronium; 17-Hydroxypancuronium; Androstane, piperidinium deriv; UNII-VD6L56ZVX1;

IUPAC/Chemical Name: 1,1'-((2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-acetoxy-17-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-2,16-diyl)bis(1-methylpiperidin-1-ium)


InChi Code: InChI=1S/C33H58N2O3/c1-23(36)38-30-20-24-12-13-25-26(33(24,3)22-29(30)35(5)18-10-7-11-19-35)14-15-32(2)27(25)21-28(31(32)37)34(4)16-8-6-9-17-34/h24-31,37H,6-22H2,1-5H3/q+2/t24-,25+,26-,27-,28-,29-,30-,31-,32-,33-/m0/s1

SMILES Code: CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@]4(C)[C@@H](O)[C@H](C[C@@H]34)[N+]5(C)CCCCC5)[C@@]2(C)C[C@@H]1[N+]6(C)CCCCC6

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 530.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Baden JM. Anticholinergic actions of steroid muscle relaxants. Anaesthesia. 1976 Mar;31(2):215-8. PubMed PMID: 937668.

2: Koo YA, Lee B, Park HJ, Choi J, Lee E, Choi D. Altered vascular endothelial growth factor expression during GnRH antagonist protocol in women of reproductive age with normal baseline hormone profiles. Fertil Steril. 2009 Mar;91(3):744-8. doi: 10.1016/j.fertnstert.2007.12.068. Epub 2008 Mar 5. PubMed PMID: 18321491.

3: Rechberger T, Baranowski W, Bogusiewicz M, Postawski K, Jakimiuk AJ, Tomaszewski J, Kulik-Rechberger B, Jakowicki JA. Serum concentrations of markers of type I collagen metabolism in women taking monophasic oral contraceptives. Ginekol Pol. 2002 Feb;73(2):81-6. PubMed PMID: 12001776.

4: Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008 Aug;90(2):395-400. Epub 2007 Oct 24. PubMed PMID: 17919608.

5: Feldman SA, Tyrrell MF. A new steroid muscle relaxant. Dacuronium-NB.68 (Organon). Anaesthesia. 1970 Jul;25(3):349-55. PubMed PMID: 4246972.

6: Mercilon--a new low-dose combined oral contraceptive. Drug Ther Bull. 1989 Jun 26;27(13):51-2. Erratum in: Drug Ther Bull 1989 Oct 2;27(20):80. PubMed PMID: 2535273.

7: Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms oestrogen. Contraception. 1992 Nov;46(5):477-88. Review. PubMed PMID: 1458894.

8: Uchikova E, Malinova M, Pekhlivanov B, Ledzhev I. [Hemostatic profile of women using low-dose oral contraceptive Mercilon. (Preliminary report)]. Akush Ginekol (Sofiia). 2002;41(3):23-5. Bulgarian. PubMed PMID: 12145973.

9: Kirkman RJ, Pedersen JH, Fioretti P, Roberts HE. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception. 1994 Jan;49(1):33-46. PubMed PMID: 8137624.

10: Agoston S, Crul EJ, Kersten UW, Houwertjes MC, Scaf AH. The relationship between disposition and duration of action of congeneric series of steroidal neuromuscular blocking agents. Acta Anaesthesiol Scand. 1977;21(1):24-30. PubMed PMID: 842267.

11: Norman J, Katz RL. Some effects of the steroidal muscle relaxant, dacuronium bromide, in anaesthetized patients. Br J Anaesth. 1971 Apr;43(4):313-9. PubMed PMID: 4252525.

12: Basdevant A, Conard J, Pelissier C, Guyene TT, Lapousterle C, Mayer M, Guy-Grand B, Degrelle H. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. Contraception. 1993 Sep;48(3):193-204. PubMed PMID: 8222650.

13: Akerlund M, Røde A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol. 1993 Sep;100(9):832-8. PubMed PMID: 8218004.

14: Coenen CM, Thomas CM, Borm GF, Hollanders JM, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996 Mar;53(3):171-6. PubMed PMID: 8689882.

15: Song S, Chen JK, Yang PJ, He ML, Li LM, Fan BC, Rekers H, Fotherby K. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception. 1992 Jun;45(6):523-32. PubMed PMID: 1535580.

16: Booij LH, Vree TB, Crul JE. Org-NC45: a new steroidal non-depolarizing muscle relaxant. Pharm Weekbl Sci. 1982 Feb 19;4(1):1-4. Review. PubMed PMID: 6122196.

17: Djurica S, Cirović M, Lukić B, Gregorić G, Tasovac-Ponomarev D. Some extrathyroid regulatory mechanisms' aspects in thyroid humoral state at the delivery. Mater Med Pol. 1990 Jul-Sep;22(3):198-201. PubMed PMID: 2132426.

18: Lukić B, Barjaktarović N. Sister-chromatid exchanges in newborns after normal and progesterone-treated pregnancies. Mutat Res. 1987 Jun;191(2):121-4. PubMed PMID: 3600694.

19: Minnema MC, Janssen HL, Niermeijer P, de Man RA. Budd-Chiari syndrome: combination of genetic defects and the use of oral contraceptives leading to hypercoagulability. J Hepatol. 2000 Sep;33(3):509-12. PubMed PMID: 11020010.